Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 7,010,000 shares, a drop of 15.1% from the March 31st total of 8,260,000 shares. Based on an average daily volume of 14,470,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 9.2% of the company’s shares are sold short.

Analysts Set New Price Targets

IVVD has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research note on Wednesday, March 26th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Invivyd in a report on Thursday, March 20th.

Invivyd Trading Up 3.5 %

NASDAQ IVVD opened at $0.63 on Monday. The firm has a market capitalization of $75.38 million, a PE ratio of -0.32 and a beta of 0.41. The business’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $0.77. Invivyd has a 12 month low of $0.35 and a 12 month high of $2.74.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million. As a group, analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently bought and sold shares of IVVD. Two Sigma Investments LP grew its holdings in Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares during the period. Two Sigma Advisers LP boosted its position in shares of Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after purchasing an additional 282,100 shares in the last quarter. Mithril II GP LP acquired a new stake in Invivyd during the fourth quarter worth approximately $4,981,000. Deutsche Bank AG increased its holdings in Invivyd by 35.2% in the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock worth $385,000 after purchasing an additional 227,463 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Invivyd by 290.5% in the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after buying an additional 87,358 shares during the period. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.